Background As the incidence of HPV/p16-positve oropharyngeal squamous cell carcinoma (OPSCC) continues to rise, a large population of survivors with treatment related morbidity is emerging. Transoral robotic surgery (TORS) is an excellent surgical option for p16-positive OPSCC but data comparing both survival and swallowing outcomes of this treatment versus radiotherapy/chemoradiotherapy (RT/CRT) remains limited. Methods Data was prospectively collected (05/2014 - 02/2019) in a tertiary care referral center from OPSCC patients treated with curative intent by TORS (+/-post-operative RT/CRT) or RT/CRT. Surgical and non-surgical treatment groups were case-matched for smoking status, T-stage, and N-stage based on AJCC 8th edition staging. Patients who were treated with curative intent by TORS (+/-post-operative RT/CRT) or RT/CRT for OPSCC were included. Overall survival, recurrence free survival, aspiration free survival and gastrostomy tube outcomes were compared using univariate and multivariate statistical analyses. Results A total of 82 patients treated with TORS were case-matched with 61 patients who received RT/CRT. TORS patients demonstrated a significantly (p=0.02) higher overall survival (OS) at 3 years (OS=93.2%) compared to RT/CRT patients (OS=78.9%). No statistically significant difference was seen in recurrence free survival when comparing the two groups. TORS patients demonstrated an aspiration free survival (AFS) of 64.7% compared to 26.1% in RT/CRT patients (p=0.02 Log-Rank, 0.018 Breslow). TORS patients also had significantly (p < 0.01) lower gastrostomy tube placement (13.4%) compared to RT/CRT (22.9%) at any point during treatment. Conclusion Patients undergoing treatment by TORS may have comparable survival and improved swallowing outcomes when compared to those undergoing RT/CRT for HPV-OPSCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.